< Previous page
All
Airlines/Aviation
Auto
Maritime/Shipbuilding
Transportation
Computer Hardware
Computer Networks
Computer Software
Computer/Electronics
Electronic Commerce
Electronic Components
High Tech Security
Internet Technology
Peripherals
Semiconductors
Electronics Gaming
Consumer Electronics
Mobile Entertainment
Multimedia/Online/Internet
Telecommunications
Household/Consumer/Cosmetics
Retail
Supermarkets
Toys
Alternative Energies
Chemical
Mining/Metals
Oil/Energy
Environmental Products & Services
Green Technology
Art
Cosmetics & Personal Care
Entertainment
Fashion
Film & Motion Picture
Jewelry
Banking/Financial Service
Insurance
Workforce Management/Human Resources
Education
Higher Education
Biotechnology
Health Care/Hospital
Infectious Disease Control
Medical Equipment
Medical/Pharmaceuticals
Agriculture
Machinery
Paper/Forest Products/Containers
Textiles
Domestic policy
Legal issues
Sports
Hotels and Resorts
Leisure/Travel/Hotels
Travel
Restaurants
Beer, Wine & Spirits
Beverages
Non-Alcoholic Beverages
Food/Beverages
Advertising
Books
Music
Publishing/Information Service
Television
Trade show news
Real Estate
Construction/Building
Furniture & Furnishings
|
Title only
|
Print
Next page >
88IV - PR Newswire Asia's news - Health Care/Hospital
5
Beauty Farm 1H2026 Net Profit Surges 40%, Reinforcing Its Industry Leadership
1H2026 Performance Highlights: ...
2026-08-28T
Banking/Financial Service
Cosmetics & Personal Care
Health Care/Hospital
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
HONG KONG , Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high ...
2026-08-28T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
NECA Expands Telehealth Care with New Counselling and Dietitian Support
NeuroEndocrine Cancer Australia strengthens free specialist support for patients, carers, and families affected by neuroendocrine cancer. ...
2026-08-28T
Health Care/Hospital
Medical/Pharmaceuticals
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
INCHEON, South Korea , Aug. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in ...
2026-08-28T
Biotechnology
Chemical
Health Care/Hospital
Medical/Pharmaceuticals
Kazia Therapeutics Limited Announces Proposed Public Offering
SYDNEY , Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies ...
2026-08-28T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
Durable Complete Metabolic Response Ongoing Since November 2025 ...
2026-08-28T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Global genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer care
MELBOURNE, Australia , Aug. 28, 2026 /PRNewswire/ -- Global multi-omics leader Novogene is establishing its first Australian laboratory at Cabrini Health, bringing advanced genomic capabilities closer ...
2026-08-28T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
CS2009 Achieved Key Clinical Validations for Efficacy and Safety ...
2026-08-27T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery ...
2026-08-27T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed ...
2026-08-27T
Biotechnology
Health Care/Hospital
Medical Equipment
Medical/Pharmaceuticals
< Previous page
Next page >
Disclaimer :
In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.